<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(7)</volume><submitter>Miller PE</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Although a large body of literature has been devoted to examining the relationship between eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure, past systematic reviews have been hampered by narrow inclusion criteria and a limited scope of analytical subgroups. In addition, no meta-analysis to date has captured the substantial volume of randomized controlled trials (RCTs) published in the past 2 years. The objective of this meta-analysis was to examine the effect of EPA+DHA, without upper dose limits and including food sources, on blood pressure in RCTs.&lt;h4>Methods&lt;/h4>Random-effects meta-analyses were used to generate weighted group mean differences and 95% confidence intervals (CIs) between the EPA+DHA group and the placebo group. Analyses were condu</pubmed_abstract><journal>American journal of hypertension</journal><pagination>885-96</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4054797</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials.</pubmed_title><pmcid>PMC4054797</pmcid><pubmed_authors>Van Elswyk M</pubmed_authors><pubmed_authors>Alexander DD</pubmed_authors><pubmed_authors>Miller PE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials.</name><description>&lt;h4>Background&lt;/h4>Although a large body of literature has been devoted to examining the relationship between eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure, past systematic reviews have been hampered by narrow inclusion criteria and a limited scope of analytical subgroups. In addition, no meta-analysis to date has captured the substantial volume of randomized controlled trials (RCTs) published in the past 2 years. The objective of this meta-analysis was to examine the effect of EPA+DHA, without upper dose limits and including food sources, on blood pressure in RCTs.&lt;h4>Methods&lt;/h4>Random-effects meta-analyses were used to generate weighted group mean differences and 95% confidence intervals (CIs) between the EPA+DHA group and the placebo group. Analyses were condu</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Jul</publication><modification>2025-04-05T10:38:38.716Z</modification><creation>2019-03-27T01:30:01Z</creation></dates><accession>S-EPMC4054797</accession><cross_references><pubmed>24610882</pubmed><doi>10.1093/ajh/hpu024</doi></cross_references></HashMap>